Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curdin Conrad

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
Science Advances|July 3, 2024
Targeting IL-1 controls refractory pityriasis rubra pilarisEloi Schmauch, Yannik Severin, Xianying Xing, et al.
American Journal of Clinical Dermatology|March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
Science Advances|July 3, 2024
Targeting IL-1 controls refractory pityriasis rubra pilarisEloi Schmauch, Yannik Severin, Xianying Xing, et al.
American Journal of Clinical Dermatology|March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 12